These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 16478727)

  • 21. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity.
    Schmidt JJ; Stafford RG
    Biochemistry; 2005 Mar; 44(10):4067-73. PubMed ID: 15751983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular basis of activation of endopeptidase activity of botulinum neurotoxin type E.
    Kukreja RV; Sharma SK; Singh BR
    Biochemistry; 2010 Mar; 49(11):2510-9. PubMed ID: 20178376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution.
    Hanson MA; Stevens RC
    Nat Struct Biol; 2000 Aug; 7(8):687-92. PubMed ID: 10932255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma membrane localization signals in the light chain of botulinum neurotoxin.
    Fernández-Salas E; Steward LE; Ho H; Garay PE; Sun SW; Gilmore MA; Ordas JV; Wang J; Francis J; Aoki KR
    Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3208-13. PubMed ID: 14982988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation.
    Kumaran D; Eswaramoorthy S; Furey W; Navaza J; Sax M; Swaminathan S
    J Mol Biol; 2009 Feb; 386(1):233-45. PubMed ID: 19118561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reengineering the specificity of the highly selective Clostridium botulinum protease via directed evolution.
    Dyer RP; Isoda HM; Salcedo GS; Speciale G; Fletcher MH; Le LQ; Liu Y; Brami-Cherrier K; Malik SZ; Vazquez-Cintron EJ; Chu AC; Rupp DC; Jacky BPS; Nguyen TTM; Katz BB; Steward LE; Majumdar S; Brideau-Andersen AD; Weiss GA
    Sci Rep; 2022 Jun; 12(1):9956. PubMed ID: 35705606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insights into the different catalytic activities of Clostridium neurotoxins.
    Chen S; Karalewitz AP; Barbieri JT
    Biochemistry; 2012 May; 51(18):3941-7. PubMed ID: 22510015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity.
    Segelke B; Knapp M; Kadkhodayan S; Balhorn R; Rupp B
    Proc Natl Acad Sci U S A; 2004 May; 101(18):6888-93. PubMed ID: 15107500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity.
    Ahmed SA; Olson MA; Ludivico ML; Gilsdorf J; Smith LA
    Protein J; 2008 Apr; 27(3):151-62. PubMed ID: 18213512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural basis of cell surface receptor recognition by botulinum neurotoxin B.
    Chai Q; Arndt JW; Dong M; Tepp WH; Johnson EA; Chapman ER; Stevens RC
    Nature; 2006 Dec; 444(7122):1096-100. PubMed ID: 17167418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum neurotoxin detection and differentiation by mass spectrometry.
    Barr JR; Moura H; Boyer AE; Woolfitt AR; Kalb SR; Pavlopoulos A; McWilliams LG; Schmidt JG; Martinez RA; Ashley DL
    Emerg Infect Dis; 2005 Oct; 11(10):1578-83. PubMed ID: 16318699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A yeast assay probes the interaction between botulinum neurotoxin serotype B and its SNARE substrate.
    Fang H; Luo W; Henkel J; Barbieri J; Green N
    Proc Natl Acad Sci U S A; 2006 May; 103(18):6958-63. PubMed ID: 16636286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes.
    Baldwin MR; Barbieri JT
    Biochemistry; 2007 Mar; 46(11):3200-10. PubMed ID: 17311420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme.
    Ambrin G; Kumar R; Singh BR
    Toxicon; 2018 Mar; 144():34-41. PubMed ID: 29309744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity.
    Jin R; Rummel A; Binz T; Brunger AT
    Nature; 2006 Dec; 444(7122):1092-5. PubMed ID: 17167421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substrate binding mode and its implication on drug design for botulinum neurotoxin A.
    Kumaran D; Rawat R; Ahmed SA; Swaminathan S
    PLoS Pathog; 2008 Sep; 4(9):e1000165. PubMed ID: 18818739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Site-directed mutagenesis identifies active-site residues of the light chain of botulinum neurotoxin type A.
    Rigoni M; Caccin P; Johnson EA; Montecucco C; Rossetto O
    Biochem Biophys Res Commun; 2001 Nov; 288(5):1231-7. PubMed ID: 11700044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a fusion protein SNVP as substrate for assaying multi-serotype botulinum neurotoxins.
    Luo S; Li T; Wang Q; Tian R; Liu H; Fang H; Chen F; Wang H
    Anal Biochem; 2014 Oct; 463():75-81. PubMed ID: 23851341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B.
    Masuyer G; Beard M; Cadd VA; Chaddock JA; Acharya KR
    J Struct Biol; 2011 Apr; 174(1):52-7. PubMed ID: 21078393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system.
    Tsai YC; Maditz R; Kuo CL; Fishman PS; Shoemaker CB; Oyler GA; Weissman AM
    Proc Natl Acad Sci U S A; 2010 Sep; 107(38):16554-9. PubMed ID: 20823219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.